Novartis FY2026 EPS Estimate Increased by Erste Group Bank

Novartis AG (NYSE:NVS) – Research analysts at Erste Group Bank lifted their FY2026 earnings per share estimates for shares of Novartis in a note issued to investors on Friday, September 18th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $9.14 for the year, up from their prior estimate of $8.99. The consensus estimate for Novartis’ current full-year earnings is $8.85 per share.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

Other analysts have also recently issued research reports about the stock. HSBC upgraded shares of Novartis from a “reduce” rating to a “hold” rating and raised their price objective for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Deutsche Bank Aktiengesellschaft cut Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Royal Bank Of Canada initiated coverage on Novartis in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Finally, Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average target price of $153.00.

Novartis Trading Up 0.6%

Shares of Novartis stock opened at $141.28 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. Novartis has a 1 year low of $121.57 and a 1 year high of $170.46. The firm has a market cap of $269.58 billion, a PE ratio of 21.31, a PEG ratio of 2.72 and a beta of 0.45. The company has a 50 day simple moving average of $152.37 and a two-hundred day simple moving average of $151.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Fisher Asset Management LLC grew its position in Novartis by 3.1% during the 4th quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock worth $1,029,317,000 after acquiring an additional 226,484 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Novartis by 9.1% in the first quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after purchasing an additional 413,778 shares during the last quarter. Auto Owners Insurance Co increased its stake in shares of Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock worth $638,103,000 after buying an additional 4,594,726 shares during the period. Franklin Resources Inc. increased its stake in shares of Novartis by 10.3% in the fourth quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock worth $617,562,000 after buying an additional 419,988 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in Novartis by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock valued at $347,649,000 after buying an additional 41,520 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

About Novartis

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.